What is the optimal antihypertensive regimen for a 72-year-old male with chronic kidney disease and atrial fibrillation who is on metoprolol succinate 50 mg extended‑release, rivaroxaban 15 mg daily, losartan 100 mg daily, and nifedipine 60 mg daily but still has uncontrolled blood pressure?

Add a Thiazide-Like Diuretic to Your Current Regimen

For this 72-year-old with CKD, atrial fibrillation, and uncontrolled hypertension on losartan 100mg, nifedipine 60mg, and metoprolol 50mg ER, add a thiazide-like diuretic (chlorthalidone 12.5-25mg or indapamide 1.25-2.5mg daily) as the next step.

Rationale for Adding a Thiazide-Like Diuretic

Your patient is already on three antihypertensive agents from different classes (ARB, calcium channel blocker, and beta-blocker), yet blood pressure remains elevated. The 2020 International Society of Hypertension guidelines 1 provide a clear stepwise algorithm: after maximizing ARB and CCB doses, the next step is adding a thiazide or thiazide-like diuretic. The 2009 Canadian guidelines 2 specifically recommend thiazide diuretics as additive therapy for CKD patients, noting that "in most cases, combination therapy with other antihypertensive agents may be needed to reach target blood pressures."

The 2020 Hypertension Canada guidelines 3 reinforce this approach, stating that additional antihypertensive drugs should be chosen from first-line options when standard-dose monotherapy fails, with thiazide/thiazide-like diuretics being a cornerstone of combination therapy.

Specific Medication Recommendations

Preferred options:

• Chlorthalidone 12.5-25mg daily (more potent and longer-acting than hydrochlorothiazide)
• Indapamide 1.25-2.5mg daily (alternative thiazide-like with favorable metabolic profile)

Research evidence supports this combination specifically. A 2009 study 4 demonstrated that adding hydrochlorothiazide 12.5mg to losartan 50mg achieved better blood pressure control (133/79 mmHg) compared to doubling losartan to 100mg alone (145/83 mmHg) in hypertensive patients with stage 3 CKD, with the added benefit of reducing proteinuria.

Blood Pressure Targets in CKD

Your target should be <130/80 mmHg based on the 2020 ISH guidelines 1. The KDIGO 2021 guidelines 5 recommend even more intensive targets (<120 mmHg systolic) for certain CKD patients meeting SPRINT criteria (age >50, elevated cardiovascular risk), though this requires careful individualization based on frailty and tolerability. For a 72-year-old with CKD and AFib, <130/80 mmHg is a reasonable initial target, with consideration for more intensive control if tolerated.

Critical Monitoring Considerations

Before adding the diuretic, check:

• Serum potassium (risk of hypokalemia with thiazide)
• Serum creatinine and eGFR (establish baseline renal function)
• Electrolytes including sodium

After initiating therapy, monitor at 2-4 weeks:

• Serum potassium (thiazides can cause hypokalemia; losartan can cause hyperkalemia—these effects may balance but require monitoring)
• Renal function (creatinine, eGFR)
• Blood pressure response

The 2009 Canadian guidelines 2 specifically warn about careful monitoring when combining medications in CKD due to potential adverse effects including hypotension, hyperkalemia, and worsening renal function.

Addressing the Atrial Fibrillation Component

Your patient's metoprolol 50mg ER serves dual purposes: rate control for AFib and blood pressure management. The rivaroxaban 15mg daily is appropriate for AFib with CKD. The 2019 AHA/ACC/HRS guidelines 6 confirm that for patients with moderate CKD (CrCl 15-50 mL/min), reduced doses of direct oral anticoagulants like rivaroxaban are appropriate. Continue this regimen unchanged while optimizing blood pressure control.

If Blood Pressure Remains Uncontrolled After Adding Diuretic

Should you reach this point (resistant hypertension on 4 agents), the 2025 AHA/ACC guidelines 7 recommend:

1. First, rule out secondary causes and medication non-adherence
2. Add a mineralocorticoid receptor antagonist (MRA) such as spironolactone 12.5-25mg daily if eGFR ≥45 mL/min/1.73m²
3. Monitor potassium closely (risk of hyperkalemia with ARB + MRA combination)
4. If MRA contraindicated or not tolerated, consider amiloride, doxazosin, or centrally acting agents

Common Pitfalls to Avoid

Do not combine ACE inhibitor with ARB - The 2009 Canadian guidelines 2 and 2020 Hypertension Canada guidelines 3 explicitly state this combination is not recommended for non-proteinuric CKD patients due to increased risk of adverse effects without additional benefit.

Do not use loop diuretics unless volume overload present - Thiazide-like diuretics are preferred for hypertension management in CKD unless there is clinical volume overload, in which case loop diuretics become necessary 2.

Avoid precipitous dose escalation - The metoprolol dose is relatively modest at 50mg ER. While you could increase this for additional blood pressure and rate control benefit, prioritize adding the diuretic first as per guideline-directed stepwise therapy.

Monitor for orthostatic hypotension - At age 72, particularly when adding a fourth agent, check standing blood pressures to avoid falls and syncope.

Practical Implementation

1. Add chlorthalidone 12.5mg or indapamide 1.25mg daily (start low in elderly with CKD)
2. Recheck labs in 2-4 weeks (potassium, creatinine, electrolytes)
3. Reassess blood pressure in 4 weeks - if inadequate response, increase diuretic dose before adding fifth agent
4. Continue losartan 100mg, nifedipine 60mg, metoprolol 50mg ER, and rivaroxaban 15mg unchanged
5. Reinforce lifestyle modifications - sodium restriction <5g/day per ISH guidelines 1

This stepwise approach follows evidence-based guidelines while accounting for your patient's age, CKD, and AFib, prioritizing both cardiovascular protection and renal preservation.